US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Silexion Therapeutics Corp

0.3701

+0.00040.11%

Post-market: 0.3700-0.0001-0.03%19:10 EDT

Volume:179.94K

Turnover:67.51K

Market Cap:2.13M

PE:-0.01

High:0.3900

Open:0.3600

Low:0.3600

Close:0.3697

52wk High:77.70

52wk Low:0.3501

Shares:5.76M

Float Shares:5.67M

Volume Ratio:0.95

T/O Rate:3.17%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-56.4473

EPS(LYR):-89.5962

ROE:-897.46%

ROA:-123.27%

PB:48.41

PE(LYR):0.00

Loading ...

Overview Company News Filings

After Moderna’s $44B Oncology Win, Silexion’s Pancreatic Cancer Treatment is Worth Exploring (NASDAQ: SLXN)

Silexion Therapeutics Announces Extraordinary Shareholder Meeting

Silexion Therapeutics Faces NASDAQ Delisting Notice over Minimum Shareholders’ Equity Shortfall

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Atai Beckley N.V. (ATAI), InspireMD (NSPR) and Silexion Therapeutics (SLXN)

Silexion Therapeutics Announces Extraordinary General Meeting

Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

THOMSON REUTERS

U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte

Top Premarket Decliners

MT Newswires Live

Silexion Therapeutics Prices USD 2.5 Million Public Offering at USD 0.65 Per Share with Warrants

Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering

THOMSON REUTERS

Immunotherapy’s Biggest Blind Spot Is a $7 Billion Market. Silexion May Have a Way In (NASDAQ: SLXN)

Silexion Therapeutics Publishes Corporate Deck Spotlighting Sil204 siRNA Program Targeting KRAS-Driven Cancers

Silexion Therapeutics files to sell ordinary shares, warrants, no amount given

Silexion Reports Preclinical Sil204 Data Supporting Phase 2/3 Development in KRAS-Driven Cancers

Silexion Therapeutics Corp - Announces Positive Preclinical Findings for Sil204 in Kras-Mutant Cancer Cells

THOMSON REUTERS

Silexion Therapeutics Director Amnon Peled Resigns for Personal Reasons

Silexion Activates First Site in Phase 2/3 Trial Targeting KRAS-Driven Pancreatic Cancer (NASDAQ: SLXN)

Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of Sil204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center

THOMSON REUTERS

Silexion Therapeutics Corp - Additional Israeli and German Sites Expected to Join Sil204 Phase 2/3 Trial in Coming Months

THOMSON REUTERS

Silexion Therapeutics Corp - Receives All Regulatory Approvals for Sil204 Trial in Israel as of July 29, 2026

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/SLXN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SLXN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","market":"US","secType":"STK","nameCN":"Silexion Therapeutics Corp","latestPrice":0.3701,"timestamp":1788292800000,"preClose":0.3697,"halted":0,"volume":179939,"hourTrading":{"tag":"盘后","latestPrice":0.37,"preClose":0.3701,"latestTime":"19:10 EDT","volume":6168,"amount":2336.2445,"timestamp":1788304240268,"change":-0.0001,"changeRate":-0.00027,"amplitude":0.05431},"delay":0,"changeRate":0.0010819583446037638,"floatShares":5672255,"shares":5755900,"eps":-56.4473,"marketStatus":"Not Yet Opened","change":0.0004,"latestTime":"09-01 16:00:00 EDT","open":0.36,"high":0.39,"low":0.36,"amount":67514.39576507,"amplitude":0.081147,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-56.4473,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788336000000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":0.3697,"preHourTrading":{"tag":"盘前","latestPrice":0.3601,"preClose":0.3697,"latestTime":"08:24 EDT","volume":5262,"amount":1897.0708683599998,"timestamp":1788265449161,"change":-0.0096,"changeRate":-0.025967,"amplitude":0.067893},"postHourTrading":{"tag":"盘后","latestPrice":0.37,"preClose":0.3701,"latestTime":"19:10 EDT","volume":6168,"amount":2336.2445,"timestamp":1788304240268,"change":-0.0001,"changeRate":-0.00027,"amplitude":0.05431},"volumeRatio":0.951303},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLXN\",,,,,undefined,":{"symbol":"SLXN","floatShares":5672255,"roa":"-123.27%","roe":"-897.46%","lyrEps":-89.596245,"volumeRatio":0.951303,"shares":5755900,"dividePrice":0,"high":0.39,"amplitude":0.081147,"preClose":0.3697,"low":0.36,"week52Low":0.3501,"pbRate":"48.41","week52High":77.7,"institutionHeld":0,"latestPrice":0.3701,"eps":-56.4473,"divideRate":0,"volume":179939,"delay":0,"ttmEps":-56.4473,"open":0.36,"prevYearClose":19.2,"prevWeekClose":0.3628,"prevMonthClose":0.3697,"prevQuarterClose":2.55,"fiveDayClose":0.365,"twentyDayClose":1.9,"sixtyDayClose":4.67},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLXN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-05-29","symbol":"SLXN","defaultRemindTime":1780061400000,"type":"split","dateTimestamp":1780027200000,"forFactor":10,"toFactor":1,"ratio":10},{"market":"US","date":"2025-07-29","symbol":"SLXN","defaultRemindTime":1753795800000,"type":"split","dateTimestamp":1753761600000,"forFactor":15,"toFactor":1,"ratio":15},{"market":"US","date":"2024-11-29","symbol":"SLXN","defaultRemindTime":1732890600000,"type":"split","dateTimestamp":1732856400000,"forFactor":9,"toFactor":1,"ratio":9},{"market":"US","date":"2024-08-13","symbol":"SLXN","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1723521600000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLXN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLXN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.5,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":2,"updateTime":1785384000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLXN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLXN","date":"2026-08-31","current":-0.006557,"percent":0.654762,"low":-1.070842,"twenty":-0.53018,"median":-0.276876,"eighty":-0.101669,"high":-0.012403,"avg":-0.330921,"sd":0.241634,"marketCap":2017260},"quantilePoints":[{"date":"2025-05-02","current":-0.511745,"twenty":-0.505522,"median":-0.478123,"eighty":-0.462658,"marketCap":8414615},{"date":"2025-05-09","current":-0.508623,"twenty":-0.511745,"median":-0.504017,"eighty":-0.475134,"marketCap":8363285},{"date":"2025-05-16","current":-0.49368,"twenty":-0.511295,"median":-0.503966,"eighty":-0.488849,"marketCap":8117579},{"date":"2025-05-23","current":-0.504427,"twenty":-0.509135,"median":-0.49826,"eighty":-0.470682,"marketCap":8294286},{"date":"2025-05-30","current":-0.491275,"twenty":-0.511407,"median":-0.49826,"eighty":-0.475032,"marketCap":8078030},{"date":"2025-06-06","current":-0.471573,"twenty":-0.511407,"median":-0.49368,"eighty":-0.475196,"marketCap":7754067},{"date":"2025-06-13","current":-0.453201,"twenty":-0.509647,"median":-0.491403,"eighty":-0.471409,"marketCap":7451983},{"date":"2025-06-20","current":-0.41963,"twenty":-0.506945,"median":-0.488844,"eighty":-0.464552,"marketCap":6899984},{"date":"2025-06-27","current":-0.415025,"twenty":-0.504283,"median":-0.484008,"eighty":-0.449824,"marketCap":6824252},{"date":"2025-07-03","current":-0.415025,"twenty":-0.504048,"median":-0.478123,"eighty":-0.41963,"marketCap":6824252},{"date":"2025-07-11","current":-0.42265,"twenty":-0.503966,"median":-0.474592,"eighty":-0.417174,"marketCap":6949630},{"date":"2025-07-18","current":-0.440049,"twenty":-0.503178,"median":-0.468758,"eighty":-0.415025,"marketCap":7235727},{"date":"2025-07-25","current":-0.430889,"twenty":-0.49932,"median":-0.464408,"eighty":-0.415332,"marketCap":7085105},{"date":"2025-08-01","current":-0.509697,"twenty":-0.49932,"median":-0.462719,"eighty":-0.415332,"marketCap":8380951},{"date":"2025-08-08","current":-0.292718,"twenty":-0.495931,"median":-0.452101,"eighty":-0.414513,"marketCap":4813156},{"date":"2025-08-15","current":-0.251096,"twenty":-0.493608,"median":-0.447572,"eighty":-0.409037,"marketCap":4128768},{"date":"2025-08-22","current":-0.231991,"twenty":-0.492964,"median":-0.436237,"eighty":-0.386752,"marketCap":3814623},{"date":"2025-08-29","current":-0.263889,"twenty":-0.49148,"median":-0.430786,"eighty":-0.303498,"marketCap":4339133},{"date":"2025-09-05","current":-0.238814,"twenty":-0.491275,"median":-0.423383,"eighty":-0.280777,"marketCap":3926818},{"date":"2025-09-12","current":-0.168193,"twenty":-0.491275,"median":-0.420859,"eighty":-0.25246,"marketCap":2765601},{"date":"2025-09-19","current":-0.12316,"twenty":-0.486413,"median":-0.417583,"eighty":-0.247343,"marketCap":2025116},{"date":"2025-09-26","current":-0.128618,"twenty":-0.486106,"median":-0.415793,"eighty":-0.244955,"marketCap":2114871},{"date":"2025-10-03","current":-0.128618,"twenty":-0.484008,"median":-0.415025,"eighty":-0.242737,"marketCap":2114871},{"date":"2025-10-10","current":-0.136465,"twenty":-0.48104,"median":-0.413413,"eighty":-0.231991,"marketCap":2243896},{"date":"2025-10-17","current":-0.121454,"twenty":-0.478123,"median":-0.409651,"eighty":-0.138853,"marketCap":1997067},{"date":"2025-10-24","current":-0.114972,"twenty":-0.478123,"median":-0.401489,"eighty":-0.132201,"marketCap":1890482},{"date":"2025-10-31","current":-0.112584,"twenty":-0.477611,"median":-0.386196,"eighty":-0.129301,"marketCap":1851214},{"date":"2025-11-07","current":-0.097914,"twenty":-0.471573,"median":-0.312505,"eighty":-0.127936,"marketCap":1609995},{"date":"2025-11-14","current":-0.097914,"twenty":-0.471163,"median":-0.292718,"eighty":-0.123842,"marketCap":1609995},{"date":"2025-11-21","current":-0.080173,"twenty":-0.468758,"median":-0.272333,"eighty":-0.121795,"marketCap":1318288},{"date":"2025-11-28","current":-0.096549,"twenty":-0.467039,"median":-0.257237,"eighty":-0.120362,"marketCap":1587556},{"date":"2025-12-05","current":-1.070842,"twenty":-0.471245,"median":-0.259284,"eighty":-0.119953,"marketCap":9902075},{"date":"2025-12-12","current":-1.0279,"twenty":-0.478706,"median":-0.282158,"eighty":-0.120362,"marketCap":9504991},{"date":"2025-12-19","current":-0.821644,"twenty":-0.486167,"median":-0.30227,"eighty":-0.120704,"marketCap":7597740},{"date":"2025-12-26","current":-0.797975,"twenty":-0.491377,"median":-0.316599,"eighty":-0.121181,"marketCap":7378875},{"date":"2026-01-02","current":-0.6492,"twenty":-0.495368,"median":-0.386196,"eighty":-0.12159,"marketCap":6003152},{"date":"2026-01-09","current":-0.710063,"twenty":-0.504027,"median":-0.401489,"eighty":-0.122205,"marketCap":6565948},{"date":"2026-01-16","current":-0.825025,"twenty":-0.510588,"median":-0.409651,"eighty":-0.122955,"marketCap":7629006},{"date":"2026-01-23","current":-0.726969,"twenty":-0.515839,"median":-0.412313,"eighty":-0.12316,"marketCap":6722280},{"date":"2026-01-30","current":-0.662725,"twenty":-0.574408,"median":-0.414769,"eighty":-0.123296,"marketCap":6128218},{"date":"2026-02-06","current":-0.510569,"twenty":-0.606596,"median":-0.415025,"eighty":-0.12391,"marketCap":4721229},{"date":"2026-02-13","current":-0.534237,"twenty":-0.597129,"median":-0.417327,"eighty":-0.124456,"marketCap":4940094},{"date":"2026-02-20","current":-0.534237,"twenty":-0.591719,"median":-0.41963,"eighty":-0.125548,"marketCap":4940094},{"date":"2026-02-27","current":-0.588338,"twenty":-0.588338,"median":-0.42265,"eighty":-0.127254,"marketCap":5440357},{"date":"2026-03-06","current":-0.557906,"twenty":-0.584956,"median":-0.42723,"eighty":-0.127936,"marketCap":5158959},{"date":"2026-03-13","current":-0.563418,"twenty":-0.591719,"median":-0.432424,"eighty":-0.128618,"marketCap":5209923},{"date":"2026-03-20","current":-0.377654,"twenty":-0.588338,"median":-0.436237,"eighty":-0.128618,"marketCap":4498612},{"date":"2026-03-27","current":-0.366297,"twenty":-0.584956,"median":-0.430786,"eighty":-0.128959,"marketCap":4363328},{"date":"2026-04-02","current":-0.341131,"twenty":-0.584956,"median":-0.423383,"eighty":-0.129233,"marketCap":4063557},{"date":"2026-04-10","current":-0.310374,"twenty":-0.584956,"median":-0.420859,"eighty":-0.131075,"marketCap":3697171},{"date":"2026-04-17","current":-0.279616,"twenty":-0.584956,"median":-0.417583,"eighty":-0.131655,"marketCap":3330785},{"date":"2026-04-24","current":-0.257275,"twenty":-0.583604,"median":-0.415793,"eighty":-0.131962,"marketCap":3064655},{"date":"2026-05-01","current":-0.171153,"twenty":-0.571093,"median":-0.415025,"eighty":-0.132167,"marketCap":2038773},{"date":"2026-05-08","current":-0.145121,"twenty":-0.564344,"median":-0.413413,"eighty":-0.133702,"marketCap":1728677},{"date":"2026-05-15","current":-0.139472,"twenty":-0.562336,"median":-0.409651,"eighty":-0.135442,"marketCap":1661395},{"date":"2026-05-22","current":-0.12255,"twenty":-0.558738,"median":-0.40296,"eighty":-0.131962,"marketCap":1582122},{"date":"2026-05-29","current":-0.138778,"twenty":-0.557906,"median":-0.397852,"eighty":-0.132133,"marketCap":1791622},{"date":"2026-06-05","current":-0.160977,"twenty":-0.557906,"median":-0.386196,"eighty":-0.133327,"marketCap":2078215},{"date":"2026-06-12","current":-0.100286,"twenty":-0.557906,"median":-0.370491,"eighty":-0.132133,"marketCap":1294694},{"date":"2026-06-18","current":-0.09412,"twenty":-0.552496,"median":-0.356785,"eighty":-0.130188,"marketCap":1215085},{"date":"2026-06-26","current":-0.088602,"twenty":-0.543705,"median":-0.341131,"eighty":-0.128209,"marketCap":1143856},{"date":"2026-07-02","current":-0.083896,"twenty":-0.541677,"median":-0.338335,"eighty":-0.124456,"marketCap":1083102},{"date":"2026-07-10","current":-0.084708,"twenty":-0.536943,"median":-0.320891,"eighty":-0.122887,"marketCap":1093576},{"date":"2026-07-17","current":-0.090225,"twenty":-0.534237,"median":-0.31317,"eighty":-0.120908,"marketCap":1164806},{"date":"2026-07-24","current":-0.077243,"twenty":-0.534237,"median":-0.309392,"eighty":-0.118588,"marketCap":997208},{"date":"2026-07-31","current":-0.059717,"twenty":-0.534237,"median":-0.302127,"eighty":-0.117019,"marketCap":770950},{"date":"2026-08-07","current":-0.058095,"twenty":-0.534237,"median":-0.293597,"eighty":-0.113607,"marketCap":750001},{"date":"2026-08-14","current":-0.014929,"twenty":-0.532214,"median":-0.288004,"eighty":-0.102349,"marketCap":192737},{"date":"2026-08-21","current":-0.158944,"twenty":-0.532214,"median":-0.280777,"eighty":-0.100286,"marketCap":2218542},{"date":"2026-08-28","current":-0.143488,"twenty":-0.530856,"median":-0.278246,"eighty":-0.101584,"marketCap":2002804},{"date":"2026-08-31","current":-0.144524,"twenty":-0.53018,"median":-0.276876,"eighty":-0.101669,"marketCap":2017260}],"updateTime":1788324789930},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLXN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662737518","title":"After Moderna’s $44B Oncology Win, Silexion’s Pancreatic Cancer Treatment is Worth Exploring (NASDAQ: SLXN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2662737518","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662737518?lang=en_us&edition=fundamental","pubTime":"2026-08-25 21:00","pubTimestamp":1787662814,"startTime":"0","endTime":"0","summary":"WSW, NY, August 25th, 2026, FinanceWire Moderna’s cancer news sent its stock up 177% in a single day (NASDAQ:MRNA), from $62.96 to $174.38. Roughly...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/after-modernas-44b-oncology-win-silexions-pancreatic-cancer-treatment-is-worth-exploring-nasdaq-slxn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/after-modernas-44b-oncology-win-silexions-pancreatic-cancer-treatment-is-worth-exploring-nasdaq-slxn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4551","GPIQ","BK4588","SQQQ","QQQY","JEPQ","IDNA","QQQ","MRNX","QYLG","QDTE","PSQ","BK4585","QQQJ","IYW","QQQE","QLD","TECS","BK4532","TQQY","QQQM","WDNA","SLXN","FTEC","BK4568","BK4501","LGHT","NDX","ONEQ","MNQmain","BK4548","BK4534","MRNY","QQQA","MRNA","BK4533",".IXIC","QID","BK4139","GNOM","NQmain","TQQQ","NVIW.SI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662323217","title":"Silexion Therapeutics Announces Extraordinary Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2662323217","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662323217?lang=en_us&edition=fundamental","pubTime":"2026-08-25 20:37","pubTimestamp":1787661459,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics announces extraordinary shareholder meetingSilexion Therapeutics will hold an extraordinary general meeting in Ramat Gan, Israel on Sept. 9, 2026.Shareholders will vote on increasing authorized share capital by 175,000,000 ordinary shares to 190,900,000 shares.A separate proposal seeks approval for a reverse share split at a ratio between 1-for-7 and 1-for-15.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 24, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nNDL80SMdr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661297157","title":"Silexion Therapeutics Faces NASDAQ Delisting Notice over Minimum Shareholders’ Equity Shortfall","url":"https://stock-news.laohu8.com/highlight/detail?id=2661297157","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661297157?lang=en_us&edition=fundamental","pubTime":"2026-08-22 04:21","pubTimestamp":1787343712,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics faces Nasdaq delisting notice over minimum shareholders’ equity shortfallNasdaq issued a delisting notice on Aug. 18, 2026 over non-compliance with the $2.5 million minimum share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL8bv9x1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660542263","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Atai Beckley N.V. (ATAI), InspireMD (NSPR) and Silexion Therapeutics (SLXN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2660542263","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660542263?lang=en_us&edition=fundamental","pubTime":"2026-08-20 00:30","pubTimestamp":1787157016,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Atai Beckley N.V. (ATAI), InspireMD (NSPR) and Sil...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-atai-beckley-n-v-atai-inspiremd-nspr-and-silexion-therapeutics-slxn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-atai-beckley-n-v-atai-inspiremd-nspr-and-silexion-therapeutics-slxn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","XBI","NSPR","XLV","BK4588","BK4539","LABU","HCSG","LU0029874061.USD","SLXN","BK4581","LU0128526141.USD","BK4198","BK4139","BK4007","ATAI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659129788","title":"Silexion Therapeutics Announces Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2659129788","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659129788?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:34","pubTimestamp":1786739654,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics announces extraordinary general meetingSilexion Therapeutics will hold an extraordinary general meeting in September 2026 at Meitar Law Offices in Ramat Gan, Israel.Shareholders ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL4zZPVy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659419521","title":"Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659419521","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659419521?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:45","pubTimestamp":1786711501,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nTUAC8WBH0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659092299","title":"U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte","url":"https://stock-news.laohu8.com/highlight/detail?id=2659092299","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659092299?lang=en_us&edition=fundamental","pubTime":"2026-08-13 00:17","pubTimestamp":1786551433,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Sutro Biopharma, HumacyteAugust 12 (Reuters)-Wall Street's main indexes rose on Wednesday, with the Nasdaq outperforming peers as upbeat earnings from AI infrastructure fi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL6N4490YK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIVI","SLNCF","CIEN","OPLN","HRB","SVV","ANNX","SMCI","OFAL","ABSI","CRWV","NCMI","UFO","WXM","LUMA","TAN","LAZR","UAMY","EGGY","EAT","ALT","TECH","NBIS","SMCL","SLXN","LQDA","SMMT","TRMB","O","DPRE","SLN","HUMA","BETA","CAVA","FSLR","STRO","EROC","SMWB","NBIZ","LOCL","CHTR","LITE","GAP","NBIX","CORD","DFTX","NTHI","PFGC","TPL","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658974868","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2658974868","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658974868?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:22","pubTimestamp":1786533726,"startTime":"0","endTime":"0","summary":"Planet Green  shares were down more than 77% premarket Wednesday after an over 927% rise in the previous close.Silexion Therapeutics  stock was 54% lower after the company priced a $2.5 million securities offering.WF International  shares were down 31%, swinging from Tuesday's 98% rise.Snail  stock was 24% lower following its Q2 financial results.Concorde International Group  shares were down nearly 24%, paring Tuesday's 33% rise.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4085","BK4086","CIGL","SLXN","SNAL","PLAG","BK4165","BK4139","WXM","BK4212"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658941792","title":"Silexion Therapeutics Prices USD 2.5 Million Public Offering at USD 0.65 Per Share with Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2658941792","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658941792?lang=en_us&edition=fundamental","pubTime":"2026-08-12 08:01","pubTimestamp":1786492877,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics prices USD 2.5 million public offering at USD 0.65 per share with warrantsSilexion Therapeutics priced a USD 2.5 million public offering of 3,846,161 ordinary shares or equivalen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL6CPcTJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","IE00BN0W2T93.GBP","SLXN","SG9999014013.SGD","SG9999014021.USD","LU0314104364.USD","IE00BKPKM429.USD","LU2210150020.SGD","IE00BN0W2V16.EUR","SG9999014039.USD","SG9999014005.SGD","BK4139","IE00BGHQF748.EUR","BK4112","LU2095319765.USD","BK4585","IE00BN0W2W23.USD","IE00B64PRP62.GBP","NDAQ","BK4588","IE00B3QW5Z07.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658941796","title":"Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2658941796","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658941796?lang=en_us&edition=fundamental","pubTime":"2026-08-12 08:01","pubTimestamp":1786492860,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nTUATND69:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658372956","title":"Immunotherapy’s Biggest Blind Spot Is a $7 Billion Market. Silexion May Have a Way In (NASDAQ: SLXN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658372956","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658372956?lang=en_us&edition=fundamental","pubTime":"2026-08-11 03:30","pubTimestamp":1786390213,"startTime":"0","endTime":"0","summary":"WSW, NY, August 10th, 2026, FinanceWire Checkpoint inhibitors are drugs that remove the “brakes” cancer puts on the immune system, letting the body...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/immunotherapys-biggest-blind-spot-is-a-7-billion-market-silexion-may-have-a-way-in-nasdaq-slxn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/immunotherapys-biggest-blind-spot-is-a-7-billion-market-silexion-may-have-a-way-in-nasdaq-slxn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QQQM","JEPQ","FTEC","QQQ","GPIQ","TQQQ",".IXIC","NVIW.SI","PSQ","SLXN","QQQJ","ONEQ","QLD","TQQY","NDX","QQQE","QDTE","SQQQ","MNQmain","QYLG","IYW","BK4139","QQQA","NQmain","QID","TECS","QQQY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658672068","title":"Silexion Therapeutics Publishes Corporate Deck Spotlighting Sil204 siRNA Program Targeting KRAS-Driven Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2658672068","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658672068?lang=en_us&edition=fundamental","pubTime":"2026-08-09 20:41","pubTimestamp":1786279307,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics publishes corporate deck spotlighting SIL204 siRNA program targeting KRAS-driven cancersSilexion highlighted SIL204, a second-generation siRNA designed to silence KRAS expression","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260809:nNDL4dLvQl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657629937","title":"Silexion Therapeutics files to sell ordinary shares, warrants, no amount given","url":"https://stock-news.laohu8.com/highlight/detail?id=2657629937","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657629937?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:45","pubTimestamp":1786135543,"startTime":"0","endTime":"0","summary":"16:40 EDT Silexion Therapeutics (SLXN) files to sell ordinary shares, warrants, no amount given Published first on TheFly – the ultimate source for...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-files-to-sell-ordinary-shares-warrants-no-amount-given-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/silexion-therapeutics-files-to-sell-ordinary-shares-warrants-no-amount-given-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LENZ","BK4007","BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656559067","title":"Silexion Reports Preclinical Sil204 Data Supporting Phase 2/3 Development in KRAS-Driven Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2656559067","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656559067?lang=en_us&edition=fundamental","pubTime":"2026-08-04 21:16","pubTimestamp":1785849372,"startTime":"0","endTime":"0","summary":"Silexion reports preclinical SIL204 data supporting Phase 2/3 development in KRAS-driven cancersSilexion Therapeutics reported new preclinical results for SIL204, extending earlier findings disclosed ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL3xJwvC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","LU2210149790.SGD","IE00BKPKM429.USD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","BK4112","LU2095319765.USD","BK4139","BK4585","NDAQ","LU2210150020.SGD","SLXN","SG9999014021.USD","LU0314104364.USD","SG9999014005.SGD","IE00B64PRP62.GBP","BK4588","BCDF","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","SG9999014039.USD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656559706","title":"Silexion Therapeutics Corp - Announces Positive Preclinical Findings for Sil204 in Kras-Mutant Cancer Cells","url":"https://stock-news.laohu8.com/highlight/detail?id=2656559706","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656559706?lang=en_us&edition=fundamental","pubTime":"2026-08-04 21:15","pubTimestamp":1785849330,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nFWN4411EJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656996183","title":"Silexion Therapeutics Director Amnon Peled Resigns for Personal Reasons","url":"https://stock-news.laohu8.com/highlight/detail?id=2656996183","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656996183?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:07","pubTimestamp":1785528442,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics director Amnon Peled resigns for personal reasonsProfessor Amnon Peled resigned from the board of Silexion Therapeutics for personal reasons, effective Aug. 1, 2026.The resignati","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDL11FsMv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655895299","title":"Silexion Activates First Site in Phase 2/3 Trial Targeting KRAS-Driven Pancreatic Cancer (NASDAQ: SLXN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2655895299","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655895299?lang=en_us&edition=fundamental","pubTime":"2026-07-29 21:30","pubTimestamp":1785331817,"startTime":"0","endTime":"0","summary":"WSW, NY, July 29th, 2026, FinanceWire Silexion Therapeutics (NASDAQ:SLXN) just announced that it initiated its Phase 2/3 clinical trial of SIL204 a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/silexion-activates-first-site-in-phase-2-3-trial-targeting-kras-driven-pancreatic-cancer-nasdaq-slxn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/silexion-activates-first-site-in-phase-2-3-trial-targeting-kras-driven-pancreatic-cancer-nasdaq-slxn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TQQQ","QYLG","NQmain","BK4139","NDX","QLD","QQQE","QQQY","IDNA","TQQY","SLXN","ONEQ","QQQ","QDTE","NVIB","HYLG","MNQmain","MEDX","JEPQ","SQQQ","GDOC","NVIW.SI","QID","QQQA","TECS","FTEC","PSQ","QQQJ","QQQM","IYW",".IXIC","GPIQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655864843","title":"Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of Sil204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center","url":"https://stock-news.laohu8.com/highlight/detail?id=2655864843","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655864843?lang=en_us&edition=fundamental","pubTime":"2026-07-29 19:00","pubTimestamp":1785322802,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nTUA584Y51:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655861089","title":"Silexion Therapeutics Corp - Additional Israeli and German Sites Expected to Join Sil204 Phase 2/3 Trial in Coming Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2655861089","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655861089?lang=en_us&edition=fundamental","pubTime":"2026-07-29 19:00","pubTimestamp":1785322802,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nTUA584Y51:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLXN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655861009","title":"Silexion Therapeutics Corp - Receives All Regulatory Approvals for Sil204 Trial in Israel as of July 29, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2655861009","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655861009?lang=en_us&edition=fundamental","pubTime":"2026-07-29 19:00","pubTimestamp":1785322802,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nTUA584Y51:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLXN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":58,"code":"91000000","status":"200"}]}}